Calcipotriene

Catalog No.S3739 Synonyms: Calcipotriol, MC903

For research use only.

Calcipotriene (Calcipotriol, MC903) is a synthetic derivative of calcitriol, a form of vitamin D. It can induce differentiation and suppresses proliferation of keratinocytes, reversing abnormal keratinocyte changes in psoriasis, and lead to normalization of epidermal growth. Calcipotriol is a synthetic VitD3 analogue with a high affinity for the vitamin D receptor.

Calcipotriene Chemical Structure

CAS No. 112965-21-6

Selleck's Calcipotriene has been cited by 2 Publications

Purity & Quality Control

Choose Selective Vitamin Inhibitors

Biological Activity

Description Calcipotriene (Calcipotriol, MC903) is a synthetic derivative of calcitriol, a form of vitamin D. It can induce differentiation and suppresses proliferation of keratinocytes, reversing abnormal keratinocyte changes in psoriasis, and lead to normalization of epidermal growth. Calcipotriol is a synthetic VitD3 analogue with a high affinity for the vitamin D receptor.
In vitro

Calcipotriene enhances IL-10 secretion in psoriatic skin and in human T cells, induces secretion of type 2 cytokines by T cells and, significantly modulates the differentiation of DCs and T cells[1].

In vivo Calcipotriol suppresses skin cancer development in mice in a TSLP-dependent manner. Calcipotriol is a well-tolerated topical medication for psoriasis. The low concentration of calcipotriol in the clinically available formulation (0.005% ointment) dampens its effect against skin cancer development in mice[2].

Protocol (from reference)

Cell Research:[1]
  • Cell lines: Monocytes (CD14+ cells)-derived DCs
  • Concentrations: 100 nM
  • Incubation Time: 24 h or 3 days
  • Method: Cells are treated in duplicates with 100 nM calcipotriol, 1 mM betamethasone (BDP), combination of calcipotriol and betamethasone (100 nM/1 mM; ratio 1:10 as in the fixed-combination product) or a corresponding vehicle control (0.1% DMSO). Treatment is applied after the first 5 days in culture and before and throughout the 3 days of activation with LPS and IFN-γ or two days after activation with LPS and IFN-γ and throughout the last 24 h of activation.
Animal Research:[2]
  • Animal Models: genetically engineered mouse models
  • Dosages: 80 nM
  • Administration: topical

Solubility (25°C)

In vitro

DMSO 82 mg/mL
(198.73 mM)
Ethanol 82 mg/mL
(198.73 mM)
Water Insoluble

Chemical Information

Molecular Weight 412.60
Formula

C27H40O3

CAS No. 112965-21-6
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(C=CC(C1CC1)O)C2CCC3C2(CCCC3=CC=C4CC(CC(C4=C)O)O)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03596073 Recruiting Drug: Topical Calcipotriene Ointment|Other: Topical Vaseline Breast Cancer Massachusetts General Hospital November 7 2018 Phase 1
NCT03476746 Completed Drug: LEO 90100 foam|Drug: Dovobet® ointment Healthy LEO Pharma March 20 2018 Phase 1
NCT03462927 Completed Drug: MC2-01 Cream|Drug: CAL/BDP combination Psoriasis Vulgaris MC2 Therapeutics February 8 2018 Phase 2
NCT02605057 Completed Drug: LEO 80185 gel|Drug: Dovobet(r) Ointment Psoriasis Vulgaris LEO Pharma November 2015 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Calcipotriene | Calcipotriene ic50 | Calcipotriene price | Calcipotriene cost | Calcipotriene solubility dmso | Calcipotriene purchase | Calcipotriene manufacturer | Calcipotriene research buy | Calcipotriene order | Calcipotriene mouse | Calcipotriene chemical structure | Calcipotriene mw | Calcipotriene molecular weight | Calcipotriene datasheet | Calcipotriene supplier | Calcipotriene in vitro | Calcipotriene cell line | Calcipotriene concentration | Calcipotriene nmr